Transforming anti-Alzheimer’s therapy by targeting endogenous receptorrial system through ligand-conjugated nanoformulations
Ageing Research Reviews · 2026-01 · 114 · 102994
DOI: 10.1016/j.arr.2025.102994 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Ageing Research Reviews, 2026-01. Verfasst von Madhuri Gawai und 6 weiteren Autor:innen. Beteiligte Einrichtung: Division of Neurotherapeutics, Smt. Kishoritai Bhoyar College of Pharmacy, Kamptee, Nagpur, Maharashtra, India. Hauptthemen laut MEDLINE: Alzheimer Disease, Drug Delivery Systems, Nanoparticles. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 182 Literaturangaben. Gefördert von: Rashtrasant Tukadoji Maharaj Nagpur University.
Themen: Demenz
Abstract (Originalsprache)
Alzheimer's Disease (AD) is the most prevalent neurodegenerative disorder, contributing to the majority of dementia cases in the elderly globally. Characterized by progressive cognitive decline, AD is associated with complex neuropathological changes, including the accumulation of amyloid-beta (Aβ) plaques and tau tangles, synaptic loss, and neuroinflammation. One of the significant challenges in treating AD is the blood-brain barrier (BBB), which prevents many therapeutic agents from reaching the brain. Despite advancements in understanding AD's pathology, limited treatment options are available, largely due to the inability of conventional drugs to effectively target the brain. Ligand-conjugated nanoparticles (NPs) are promising for targeted drug delivery to the brain. These NPs, engineered with ligands that can bind to specific receptors or transporters on the BBB, facilitate the crossing of the barrier via receptor-mediated endocytosis or adsorptive-mediated transcytosis. This strategy enhances therapeutic agents' bioavailability and cellular uptake, offering a potential solution to overcome current limitations in AD treatment. Using nanotechnology to design ligand-conjugated NPs for targeted and sustained drug delivery could significantly improve therapeutic outcomes for AD patients by addressing key pathological processes in the brain.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Division of Neurotherapeutics, Smt. Kishoritai Bhoyar College of Pharmacy, Kamptee, Nagpur, Maharashtra, India.
- Division of Neurotherapeutics, Smt. Kishoritai Bhoyar College of Pharmacy, Kamptee, Nagpur, Maharashtra, India; Rashtrasant Tukdoji Maharaj Nagpur University, Nagpur, Maharashtra, India. Electronic address: jayabtaksand…
Förderung
- Rashtrasant Tukadoji Maharaj Nagpur University
Zitieren
APA
Gawai, M., Nistane, N., Tatode, A. A., Qutub, M., Umekar, M. J., Premchandani, T., & Taksande, J. B. (2026). Transforming anti-Alzheimer’s therapy by targeting endogenous receptorrial system through ligand-conjugated nanoformulations. Ageing Research Reviews, 114, 102994. https://doi.org/10.1016/j.arr.2025.102994
Vancouver
Gawai M, Nistane N, Tatode AA, Qutub M, Umekar MJ, Premchandani T, et al. Transforming anti-Alzheimer’s therapy by targeting endogenous receptorrial system through ligand-conjugated nanoformulations. Ageing Research Reviews. 2026;114:102994. doi:10.1016/j.arr.2025.102994
BibTeX
@article{Gawai2026,
author = {Gawai, Madhuri and Nistane, Neha and Tatode, Amol A and Qutub, Mohammad and Umekar, Milind J and Premchandani, Tanvi and Taksande, Jayshree B},
title = {Transforming anti-Alzheimer’s therapy by targeting endogenous receptorrial system through ligand-conjugated nanoformulations},
journal = {Ageing Research Reviews},
year = {2026},
volume = {114},
pages = {102994},
doi = {10.1016/j.arr.2025.102994}
}
EUVIMED